Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
29
DGX Quote, Financials, Valuation and Earnings
Last price:
$153.41
Seasonality move
:
0%
Day range:
$152.13 - $153.49
52-week range:
$123.04 - $165.32
Dividend yield:
1.93%
P/E ratio:
20.62x
P/S ratio:
1.81x
P/B ratio:
2.51x
Volume:
212.7K
Avg. volume:
892.5K
1-year change:
12.2%
Market cap:
$17.1B
Revenue:
$9.3B
EPS (TTM):
$7.44
Analysts' Opinion
-
Consensus RatingQuest Diagnostics has received a consensus rating of Hold. The company's average rating is a Hold based on 8 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $169.96, Quest Diagnostics has an estimated upside of 10.78% from its current price of $153.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $153.00 representing 0.27% downside risk from its current price of $153.42.
Fair Value
-
According to the consensus of 17 analysts, Quest Diagnostics has 10.78% upside to fair value with a price target of $169.96 per share.
DGX vs. S&P 500
-
Over the past 5 trading days, Quest Diagnostics has underperformed the S&P 500 by -4.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Quest Diagnostics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Quest Diagnostics has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Quest Diagnostics reported revenues of $2.5B.
Earnings Growth
-
Quest Diagnostics has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Quest Diagnostics reported earnings per share of $1.99.
Enterprise value:
22.7B
EV / Invested capital:
1.73x
Price / LTM sales:
1.81x
EV / EBIT:
17.31x
EV / Revenue:
2.38x
PEG ratio (5yr expected):
1.76x
EV / Free cash flow:
22.21x
Price / Operating cash flow:
16.83x
Enterprise value / EBITDA:
12.77x
Gross Profit (TTM):
$3.1B
Return On Assets:
5.89%
Net Income Margin (TTM):
8.82%
Return On Equity:
12.68%
Return On Invested Capital:
7.3%
Operating Margin:
13.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.3B | $9.3B | $9.5B | $2.3B | $2.5B | |
| Gross Profit | $3.7B | $3.1B | $3.1B | $754M | $811M | |
| Operating Income | $1.8B | $1.1B | $1.3B | $342M | $330M | |
| EBITDA | $2.2B | $1.6B | $1.8B | $451M | $479M | |
| Diluted EPS | $10.17 | $6.66 | $7.44 | $1.96 | $1.99 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.3B | $2.9B | $2.3B | $1.8B | $2.6B | |
| Total Assets | $14.1B | $13.6B | $13.2B | $13.5B | $16.1B | |
| Current Liabilities | $2.4B | $1.8B | $1.6B | $1.6B | $2.1B | |
| Total Liabilities | $7.6B | $7.1B | $6.9B | $6.9B | $9.2B | |
| Total Equity | $6.5B | $6.5B | $6.3B | $6.5B | $6.9B | |
| Total Debt | $4.6B | $4B | $4B | $4.3B | $6.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.9B | $1.1B | $1.4B | $207M | $356M | |
| Cash From Investing | -$596M | -$1.1B | -$2.2B | -$107M | -$1.6B | |
| Cash From Financing | -$1.6B | -$515M | $1.4B | -$83M | $1.8B | |
| Free Cash Flow | $1.5B | $596M | $1B | $102M | $250M | |
DGX
Sector
Market Cap
$17.1B
$46.1M
Price % of 52-Week High
92.8%
46.02%
Dividend Yield
1.93%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
12.2%
-30.52%
Beta (5-Year)
0.893
0.772
Dividend yield:
1.93%
Annualized payout:
$2.79
Payout ratio:
38.88%
Growth streak:
12 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$153.17
200-day SMA
Buy
Level
$145.96
Bollinger Bands (100)
Sell
Level
150.35 - 158.93
Chaikin Money Flow
Buy
Level
121.3M
20-day SMA
Sell
Level
$157.08
Relative Strength Index (RSI14)
Sell
Level
42.02
ADX Line
Sell
Level
10.8
Williams %R
Neutral
Level
-61.9423
50-day SMA
Sell
Level
$156.90
MACD (12, 26)
Sell
Level
-1.65
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
130.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1053)
Buy
CA Score
(Annual)
Level (0.0291)
Buy
Beneish M-Score
(Annual)
Level (-2.5584)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.6177)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Stock Forecast FAQ
In the current month, DGX has received 8 Buy ratings 9 Hold ratings, and 0 Sell ratings. The DGX average analyst price target in the past 3 months is $169.96.
-
Where Will Quest Diagnostics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Quest Diagnostics share price will rise to $169.96 per share over the next 12 months.
-
What Do Analysts Say About Quest Diagnostics?
Analysts are divided on their view about Quest Diagnostics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Quest Diagnostics is a Sell and believe this share price will drop from its current level to $153.00.
-
What Is Quest Diagnostics's Price Target?
The price target for Quest Diagnostics over the next 1-year time period is forecast to be $169.96 according to 17 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is DGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Quest Diagnostics is a Hold. 9 of 17 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DGX?
You can purchase shares of Quest Diagnostics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Quest Diagnostics shares.
-
What Is The Quest Diagnostics Share Price Today?
Quest Diagnostics was last trading at $153.41 per share. This represents the most recent stock quote for Quest Diagnostics. Yesterday, Quest Diagnostics closed at $153.42 per share.
-
How To Buy Quest Diagnostics Stock Online?
In order to purchase Quest Diagnostics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
